Cancer Survivorship in the Aging Population

Abstract

The rapidly increasing number of older adults living with and beyond cancer presents a complex array of clinical challenges for healthcare professionals. As the global population ages, cancer survivorship in this demographic demands nuanced understanding of comorbidities, functional decline, and unique psychosocial needs. This review synthesizes current evidence regarding epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, management strategies, and emerging therapies in the context of geriatric oncology. Emphasis is placed on guideline-based recommendations and the integration of multidisciplinary care to optimize outcomes for aging cancer survivors.

Introduction

The intersection of cancer and aging is a growing concern for clinicians worldwide. Advances in early detection and treatment have increased cancer survival rates, leading to a burgeoning population of elderly survivors. These individuals often contend with age-related physiological changes, multiple chronic conditions, and unique survivorship issues. Addressing the complexities of cancer survivorship in the aging population requires understanding their distinct needs, integrating comprehensive geriatric assessment, and employing evidence-based interventions tailored to improve longevity and quality of life.

Epidemiology / Disease Burden

Cancer incidence and prevalence are highest among older adults, with approximately 60% of new cancer diagnoses and 70% of cancer deaths occurring in those aged 65 years and above. Population-based studies indicate that the number of cancer survivors over 65 is expected to double within the next two decades. This demographic is at increased risk for second primary malignancies, treatment-related toxicities, and non-cancer comorbidities, which collectively drive healthcare utilization and impact survivorship outcomes. The rising burden underscores the imperative for age-specific survivorship care models.

Pathophysiology

Aging is accompanied by complex biological changes that influence cancer development, progression, and response to therapy. Hallmarks of aging including genomic instability, telomere attrition, epigenetic alterations, and cellular senescence contribute to oncogenesis and modulate tumor biology. Diminished organ reserve, altered pharmacokinetics, and impaired DNA repair mechanisms in elderly patients increase susceptibility to treatment-related adverse events and complicate therapeutic decision-making. Immune senescence further impacts the efficacy of immuno-oncologic strategies in this population.

Risk Factors

In addition to established carcinogenic exposures such as tobacco, alcohol, and radiation, older adults face cumulative risks associated with prolonged environmental exposures and age-related physiological decline. Chronic inflammation, hormonal changes, and immunosenescence contribute to increased cancer susceptibility. Comorbidities such as diabetes, cardiovascular disease, and obesity not only elevate cancer risk but also influence survivorship trajectories, complicating management and necessitating individualized care plans.

Clinical Features

Cancer survivors in the aging population often present with a constellation of symptoms that may overlap with age-related conditions. Fatigue, cognitive impairment, pain, and functional decline are prevalent and may be exacerbated by pre-existing frailty or polypharmacy. The presentation of late effects, such as cardiotoxicity, neuropathy, and secondary malignancies, may be delayed or atypical in elderly survivors, necessitating vigilant long-term surveillance and interdisciplinary assessment to distinguish between cancer-related and age-related sequelae.

Diagnosis

Diagnostic evaluation in older cancer survivors should be comprehensive, integrating standard oncologic assessment with geriatric evaluation tools. Functional status, cognitive function, nutritional assessment, and psychosocial factors should be routinely assessed to inform treatment planning. Imaging and laboratory studies must be interpreted in the context of age-related changes such as decreased renal function or altered bone marrow reserve. Risk stratification models incorporating geriatric domains can aid in identifying patients at risk for poor outcomes and guide personalized surveillance protocols.

Treatment & Management

Management of cancer survivorship in the aging population is inherently multidisciplinary. Treatment plans must balance oncologic efficacy with preservation of function, minimization of toxicity, and consideration of patient preferences. Evidence supports the use of comprehensive geriatric assessment to guide therapy selection, dose modifications, and supportive care interventions. Rehabilitation, nutritional support, and psychosocial services are integral to survivorship care. Coordination with primary care and specialty services ensures holistic management of comorbidities and prevention of late effects.

Recent Advances / Emerging Therapies

Recent advances in precision oncology, immunotherapy, and supportive care have begun to reshape survivorship paradigms for older adults. Personalized risk prediction tools, such as the Cancer and Aging Research Group (CARG) and Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) scores, facilitate individualized care. Geriatric-adapted clinical trials and real-world evidence are informing age-appropriate dosing and toxicity management. Emerging therapies including targeted agents and immunomodulatory drugs offer promise but require careful consideration of age-specific pharmacodynamics and potential interactions with existing comorbidities and medications.

Guideline Recommendations

Leading organizations, including the American Society of Clinical Oncology (ASCO) and the International Society of Geriatric Oncology (SIOG), advocate for routine integration of geriatric assessment into cancer survivorship care for older adults. Guidelines emphasize the importance of ongoing surveillance for recurrence, management of late effects, promotion of healthy aging, and advance care planning. Multidisciplinary care teams, shared decision-making, and individualized survivorship care plans are recommended to address the complex needs of elderly cancer survivors.

Conclusion

Cancer survivorship in the aging population is a multifaceted challenge requiring coordinated, evidence-based approaches. Understanding the interplay between oncologic and geriatric factors is essential for optimizing outcomes, minimizing morbidity, and enhancing the quality of life for elderly cancer survivors. Continued research, innovation in therapy, and development of age-specific guidelines will be critical to meeting the needs of this growing population of survivors.